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Background: Intima-media thickness (IMT) is a validated marker of preclinical atherosclerosis and a predictor of
cardiovascular events.
Patients: We studied a population of 529 asymptomatic patients (age 62 ± 12.8 years), divided into two groups of
subjects with and without Metabolic Syndrome (MetS).
Methods: All patients, at baseline, have had a carotid ultrasound evaluation and classified in two subgroups: the
first one without atherosclerotic lesions and the second one with preclinical atherosclerosis (increased IMT or
asymptomatic carotid plaque). Cardiovascular endpoints were investigated in a 20-years follow-up.
Results: There were 242 cardiovascular events: 144 among patients with MetS and 98 among in healthy controls
(57.4% vs. 35.2%; P < 0.0001). 63 events occurred in patients with normal carotid arteries, while 179 events occurred
in patients with preclinical atherosclerosis (31.8% vs. 54.1%; P < 0.0001). Of the 144 total events occurred in patients
with MetS, 36 happened in the subgroup with normal carotid arteries and 108 in the subgroup with preclinical
atherosclerosis (45% vs. 63.15%; P = 0.009). 98 events occurred in patients without MetS, of which 27 in the subgroup
with normal carotid arteries and 71 in the subgroup with preclinical atherosclerosis (22.88% vs. 44.37%; P = 0.0003). In
addition, considering the 63 total events occurred in patients without atherosclerotic lesions, 36 events were recorded
in the subgroup with MetS and 27 events in the subgroup without MetS (45% vs. 22.88%; P = 0.0019). Finally, in 179
total events recorded in patients with preclinical carotid atherosclerosis, 108 happened in the subgroup with MetS and
71 happened in the subgroup without MetS (63.15% vs. 44.37%; P = 0.0009). The Kaplan-Meier function showed an
improved survival in patients without atherosclerotic lesions compared with patients with carotid ultrasound alterations
(P = 0.01, HR: 0.7366, CI: 0.5479 to 0.9904).
Conclusions: Preclinical atherosclerosis leads to an increased risk of cardiovascular events, especially if it is associated
with MetS.
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The atherosclerotic process starts in childhood and pro-
ceeds silently over a long period of time before clinical
manifestations. However, atherosclerosis is a significant
cause of death in the developed countries and quite fre-
quently it presents as a fatal event, hence the interest in
detecting it in its subclinical stages [1].
Carotid artery Intima-Media Thickness (IMT) reflects
the structural deterioration of the arterial wall, so it is
considered a significant predictive marker of generalized
atherosclerosis because of its correlation with coronary
artery disease and it may predict future cardiovascular
events in adults [1]. It is associated with established vas-
cular risk factors (hypertension, dyslipidemia, diabetes
mellitus, and smoking) or with less-conventional risk
factors such as homocysteine, inflammation markers
(C-reactive protein, fibrinogen) or uric acid [2-11].
The Metabolic Syndrome (MetS) represents a cluster-
ing of several cardiovascular (CV) risk factors including
abdominal obesity, impaired glucose intolerance, dys-
lipidemia, and hypertension, with insulin resistance as a
major characteristic [12-14]. MetS has got a high preva-
lence in the US population; in people >20 years old it is
24% and it rises to > 40% in patients ≥ 60 years of age
[15,16]. Several clinical studies recognized MetS as re-
sponsible for the endothelial dysfunction, which is the first
“step” in atherothrombotic disease and, in addition, it is
observed the association between an increased Carotid
intima-media thickness (C-IMT) and MetS [3,16-21]. The
current study is the implementation of a study published
in the month of August 2012 [22], with new data aiming
to identify the influence of carotid preclinical athero-
sclerosis on prediction of cardiovascular events during a
20-years follow-up in a population of middle-aged sub-
jects. We also evaluated the role of the metabolic syn-
drome on the risk of cardiovascular events comparing
groups with preclinical atherosclerotic lesions.
Methods
Patients
Our study was performed on a population of 529 asymp-
tomatic patients, aged between 25 and 87 years old
(62 yrs ± 12.79) at baseline, divided in 257 male patients
and 272 females, who were attending twenty years ago
our “Centre for the Early Diagnosis of Preclinical and
Multifocal Atherosclerosis and for the Cardiovascular
Prevention”, in Palermo, Italy. We identified 529 asymp-
tomatic subjects at baseline from our registry of more
than 9000 patients referred from 1985 to 1991 and in
follow-up in our centre. From this registry we selected
the population evaluated in the present study with MetS,
according to the document of Scientific International
Societies - International Diabetes Federation (IDF),
National Heart, Lung, and Blood Institute (NHLBI),World Hearth Federation, International Atherosclerosis
Society e American Heart Association (AHA) – pub-
lished in 2009 [23], which defined MetS as an alteration
in 3 or more of the following 5 components: abdominal
obesity, triglycerides, high-density lipoprotein (HDL)
cholesterol, blood pressure (BP), and fasting plasma glu-
cose. The following cut-off values were used to define
alterations: waist circumference >102 cm for men
and >88 cm for women for abdominal obesity, triglyc-
erides ≥150 mg/dL (1.69 mmol/L), HDL-cholesterol
<40 mg/dL (1.04 mmol/L) for men and < 50 mg/dL
(1.29 mmol/L) for women, BP ≥ 130/≥85 mm Hg and
fasting glucose ≥ 100 mg/dL. The choice of cutoff values
for waist circumference was done according to the recent
published consensus, taking into consideration the geo-
graphic distribution [23]. The most common CV risk fac-
tors (lifestyle, dietary habits, smoking, family and personal
history of CV disease) were investigated. Moreover we
evaluated the anthropometric parameters (weight, height,
and waist circumference) and the laboratory ones (fasting
triglycerides, HDL-c, fasting glucose and fasting insulin),
as well as blood pressure. Figure 1 shows the prevalence
of the mean cardiovascular risk factors in the population
evaluated.
Body mass index (BMI) has been calculated as weight
in kilograms divided by the square of height in meters.
Waist circumference was calculated as the average of 2
measurements taken after inspiration and expiration at
the midpoint between the lowest rib and iliac crest.
Blood pressure (BP) measurements were performed with
participants in the seated position and after a quiet rest-
ing period of 5 minutes. BP was measured in both arms
with a random-zero mercury sphygmomanometer; the
BP values used in this study are the average of the
measurements on both the right and left arms. Pulse
pressure was computed as the difference between the
systolic.
BP (SBP) and the diastolic BP (DBP). Low-density
lipoprotein (LDL) and high-density lipoprotein (HDL)
fractions were separated from fresh serum by combined
ultracentrifugation and precipitation; triglycerides were
measured enzymatically. Blood glucose was measured
using a glucose dehydrogenase method after precipita-
tion of proteins by trichloroacetic acid.
We excluded patients affected by cancer, inflammatory
bowel disease and with other autoimmune disorders be-
cause these diseases were considered as confounding
variables for their ability to power the atherosclerosis
process.
Patient’s consent
Written informed consent was obtained from the patient
for the publication of this report and any accompanying
images.
Figure 1 Prevalence of the cardiovascular risk factors in the study population.
Table 1 Mean values and standard deviation of the risk
factors included in the metabolic syndrome cluster
MetS Control
subjects
P-value
BMI (Kg/m2) 29.18±4.42 25.36±3.67 <0.0001
Waist circumference (cm) 90.80±7.99 85.09±9.41 <0.0001
Fasting blood glucose
(mg/dL)
123.272±49.32 96.77±26.49 <0.0001
Triglyceridemia (mg/dL) 174.23±78.47 127.82±35.79 <0.0001
HDL-cholesterol (mg/dL) 40.24±13.004 47.79±11.14 <0.0001
Systolic blood pressure
(mmHg)
150±1.2 125±0.09 <0.0001
Diastolic blood pressure
(mmHg)
150±1.1 90±0.8 <0.0001
BMI: body mass index; HDL: high density lipoprotein cholesterol.
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Helsinki Declaration and with international guidelines
for the research on humans.
Echo color Doppler examination of carotid arteries
Ultrasound examination was performed in all patients at
baseline, in order to investigate the presence of preclin-
ical atherosclerosis. B-mode real-time ultrasound was
used to evaluate the arterial wall thickness in the carotid
arteries using a machine Toshiba 270 SS with a probe of
7.5 to 10.0 MHz [24]. The power output, focus, depth of
measurement, and gain were standardized by using the
preset program incorporated within the software pack-
age of the ultrasound equipment. The IMT was defined
as the distance between the echogenic line representing
the intima- blood interface and the outer-echogenic line
representing the adventitia junction. After freezing the
image, the measurement was made with electronic cali-
pers. Patients were examined in the supine position, and
each carotid wall and segment was examined to identify
the thickest intimal-medial site [25]. Three segments
were identified and measured in anterior and posterior
planes on each side: the distal 1 cm of the common ca-
rotid proximal to the bifurcation, the bifurcation itself,
and the proximal 1 cm of the internal carotid artery. At
each of these sites, we have determined the IMT, auto-
matically measured, and detected any possible plaque.
We primarily used the maximum carotid IMT value,
which was determined as the mean of the maximum
IMT of near- and far-wall measurements of both the left
and right side arteries for each of the 3 arterial seg-
ments. If data on one of the walls or one of the sides
were missing, maximum thickness of the available wall
and side was used. The percentage of missing data was ≈
35% (probably because of technical difficulties in theevaluation). Ultrasound examination was performed by
one investigator, in blind and with no possibility of re-
producing the IMT measurement. Carotid ultrasonog-
raphy was performed by one sonographer to limit the
risk of a large interobserver variability. However, for
methodological correctness, the intraobserver agreement
for sonographic measurement was calculated with a
4.1% to 5.0% coefficient of variation for repeated scans.
Follow-up
Cardiovascular endpoints were investigated in a 20-years
follow-up: acute myocardial infarction (AMI), angina
pectoris, transient ischemic attack (TIA), ischemic stroke,
abdominal aortic aneurysm (AAA), thromboendarte-
rectomy (TEA) and cardiovascular death. Not fatal events
were investigated through clinical controls during the
follow-up in hospital. Fatal events were ascertained
through the interrogation of family members or death
certificates.
Table 2 Distribution of the study population according to the presence of metabolic syndrome and carotid ultrasound
examinations
IMT MetS (n=251 patients) Not MetS (n=278 patients) P-value Total (n=529 patients)
Normal 80(31.87%) 118(42.5%) P=0.015 198 patients
Increased IMT/Asymptomatic plaque 171(68.13%) 160(57.5%) P=0.015 331 patients
MetS: metabolic syndrome; IMT: intima-media thickness. Normal IMT: < 0,9 mm; Increased IMT: > 0,9 mm and < 1,5 mm; Asymptomatic carotid plaque: IMT > 1,5 mm.
Table 3 Distribution of cardiovascular events in each
subgroup of population
MetS
(251 patients)
No MetS
(278 patients)
P
Normal (198 patients) 36 events/
80 patients
27 events/
118 patients
P=0.0018
(45%) (22.88%)
Subclinical atherosclerosis
(331 patients)
108 events/
171 patients
71 events/
160 patients
P=0.0009
(63.15%) (44.37%)
P P=0.0099 P=0.0003
MetS: metabolic syndrome. Preclinical carotid atherosclerosis: increased IMT or
asymptomatic carotid plaque.
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Descriptive statistics were presented as percentages for
categorical variables and as mean values ± standard devi-
ation (SD) for continuous data. Differences between
groups were compared by the Chi-square test for cat-
egorical variables. In addition, free-events survival was
tested by Kaplan-Meyer function and log-rank test. A
p-value < 0.05 was considered statistically significant.
Statistical analysis was performed using the Med Calc
Program.
Results
Our population of 529 patients was divided into two cat-
egories, a first one with 251 patients suffering from
metabolic syndrome and another one with 278 control
subjects who had from 0 to 2 risk factors, so considered
as controls. Both groups (participants with MetS and
control subjects) were homogeneous about age, gender,
smoking, diabetes and family history for CV diseases.
The mean values of each component of MetS are
showed in Table 1. According to the results of this ultra-
sound examination our patients were divided into three
categories: 198 “normal subjects” (IMT < 0,9 mm), 162
patients with increased IMT (IMT > 0,9 mm and <
1,5 mm) and 169 patients with asymptomatic carotid
plaque (IMT > 1,5 mm). In each of these groups, we
identified two subgroups of subjects with or without
MetS. Table 2 shows how it is more probable to find pa-
tients without MetS in the “normal subjects” subgroup
(P = 0.015); on the contrary, in patients with increased
IMT/asymptomatic plaque (331 patients) the presence
of MetS is more frequent (P = 0.015).
During the follow-up there were 242 cardiovascular
events: 144 in patients with MetS (251 patients) and
98 in healthy controls (278 patients); (57.4% vs. 35.2%;
P < 0.0001).
As to the presence or absence of carotid preclinical
atherosclerosis, 63 events occurred in patients with nor-
mal carotid arteries (198 patients), while 179 events oc-
curred in patients with preclinical atherosclerosis
(increased IMT/asymptomatic plaque; 331 patients);
(31.8% vs. 54.1%; P < 0.0001). In the 144 total events oc-
curred in patients with MetS, 36 happened in the sub-
group of patients with normal carotid arteries and 108
happened in the subgroup of patients with preclinical
atherosclerosis (45% vs. 63.15%; P = 0.0099). Similarly, in
the 98 total events occurred in patients without MetS,27 developed in the subgroup with normal carotid arter-
ies and 71 in the subgroup with preclinical athero-
sclerosis (22.88% vs. 44.37%; P = 0.0003). So, preclinical
atherosclerosis produced a significant increase of the risk
of events, especially in presence of MetS (Table 3;
Figure 2). In addition, in the 63 total events occurred in
patients without atherosclerotic lesions, 36 events were
recorded in the subgroup with MetS and 27 events in the
subgroup without MetS (45% vs. 22.88%; P = 0.0018). Of
the 179 total events recorded in patients with atheroscler-
otic lesions, 108 events happened in the subgroup with
MetS and 71 events in the subgroup without MetS
(63.15% vs. 44.37%; P = 0.0009). So, both in patients with
preclinical atherosclerosis and in patients without athero-
sclerotic lesions the presence of MetS increased the risk of
CV events (Table 3; Figure 3).
Finally, comparing the subgroup without MetS and
without atherosclerotic lesions to the subgroup affected
by MetS and preclinical atherosclerosis, the second
group showed a higher incidence of cardiovascular
events (22.88% vs. 63.15%; P < 0.0001); (Table 3).
The cardiovascular events occurred in the groups can
be summarized as follows (Table 4):
 In patients without preclinical atherosclerosis
(normal; 198 patients) occurred: 12 cases of angina,
11 AMI, 13 TIAs, 14 strokes, 2 AAA, 1 TEA and 10
cardiovascular deaths.
 In patients with carotid ultrasound lesions (IMT or
asymptomatic plaque; 331 patients) occurred: 21
cases of angina pectoris, 49 AMI, 35 TIAs, 33
strokes, 4 AAA, 4 TEA and 33 cardiovascular
deaths.
Figure 2 Comparison of incidence of events in the subgroups of study.
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osis, the event-free survival was evaluated in patients
with and without carotid ultrasound lesions by Kaplan
Meyer function (Figure 4). It showed an improved
survival in patients who had not atherosclerotic lesions
(P = 0.0159, HR: 0.7366, CI: 0.5479-0.9904).
Discussion
Cardiovascular diseases (CVD) are the leading cause of
morbidity and mortality in Americans and Europeans.
Signs of CVD are evident in the vessels before the onset
of clinical disease symptoms. Subclinical disease can be
measured using non-invasive B-mode ultrasound in
order to assess common carotid artery intima-media
thickness. Vascular aging is a natural process that can be
modified by lifestyle and pharmacologic interventions.
IMT is measured as the distance between the lumen-
intimal interface and the medial-adventitial interface.
The measurement varies depending on several factors:
the used carotid artery (both the left and the right side
or only one side); the artery segment(s) (common ca-
rotid, internal carotid, bulb); whether near and far wallFigure 3 Distribution of cardiovascular events in relation to preclinicaimages are used and whether plaque is included in the
measurement. Typically IMT is the average of all avail-
able segments and sides. It is reliable, reproducible [26]
and measured in a wide variety of populations [27-31].
Several studies have demonstrated the relationship be-
tween thicker IMT and/or carotid plaque and traditional
cardiovascular risk factors like age, smoking, type 2 dia-
betes, hypertension, higher low density lipoprotein
(LDL) cholesterol [27,31]. It has been also described that
preclinical atherosclerosis is associated with type 1 dia-
betes in young adults [32] and with gestational diabetes
[33,34], showing an increased C-IMT in these patients
comparing it to controls.
IMT and carotid plaque are indicators of atheroscler-
osis and predictors of myocardial infarction and cardio-
vascular mortality [35,36]. A thicker IMT predicts
coronary heart disease [28], stroke [29], and myocardial
infarction [29,31]. A 5,5 years-follow-up showed that the
risk of myocardial necrosis increases for about 10- 15%
just if IMT increases for 0,1 mm while the risk of stroke
increases for about 13- 18% [37]. Moreover other studies
underlined that the Metabolic Syndrome could producel atherosclerosis and MetS.
Table 4 Events occurred in patients with and without carotid preclinical atherosclerosis
Angina AMI TIA Stroke AAA TEA Fatal events Total events
Normal (198 patients) 12(19%) 11(17.4%) 13(19%) 14(22.2%) 2(3.17%) 1(1.58%) 10(15.9%) 63(31.8%)
IMT/Asymptomatic plaque (331 patients) 21(20%) 49(27.3%) 35(20%) 33(24%) 4(3.23%) 4(2.23%) 33(18.4%) 179(54.1%)
P P=0.003 P<0.0001
AMI: acute myocardial infarction; TIA: transient ischemic attack; AAA: abdominal aortic aneurysm; TEA: thrombo-endo-arterectomy.
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seems to be related to a low gray matter cerebral blood
flow (GM-CBF) and to a lower immediate memory func-
tion if compared to control subjects [38].
The results of IMPROVE Study (Carotid Intima-Media
Thickness [IMT] and IMT-Progression as Predictors of
Vascular Events in a High Risk European Population)
compared the performance of several measures of
C-IMT as predictors of cardiovascular events and
investigated whether they add to the predictive accur-
acy of Framingham risk factors. Therefore, this study sug-
gests that a risk stratification strategy based on C-IMT
and ICCAD (inter-adventitia common carotid artery
diameter) as an adjunct to Framingham risk factors is a
rational approach to prevent cardiovascular diseases [39].
Our data confirm the results of other clinical studies
(nationals and internationals) that have examined the re-
lationship between preclinical atherosclerosis, MetS and
CV risk [40-43].
We demonstrated that the presence of preclinical ath-
erosclerosis lead to an increased incidence of cardiovas-
cular events, especially if it is associated with MetS. In
fact, total cardiovascular events were more frequent in
the group of patients with carotid preclinical athero-
sclerosis compared to patients with normal carotid arter-
ies (P < 0.0001). Similarly, both in patients with MetSFigure 4 Event-free survival according to the Kaplan Meyer
function.and in patients without MetS cardiovascular events were
more frequent in presence of preclinical atherosclerosis
than without these lesions. Moreover, also the import-
ance of MetS resulted significant, in fact, both in pa-
tients with preclinical atherosclerosis and in patients
without atherosclerotic lesions the presence of MetS in-
creased the risk of CV events. Event-free survival was
lower in patients with preclinical atherosclerosis than in
healthy subjects (P = 0.0159, HR: 0.7366, CI 0.5479-0
0.9904).
Another study also described that progression of ca-
rotid preclinical atherosclerosis is greater especially in
cases of MetS [44]. In a study conducted on 1442 men
and 1532 women it was observed that subjects with
MetS had higher levels of IMT and total plaque area
(TPA) at follow up than those without MetS and that
Mets predicted progression of IMT and TPA in patients
below 50 years old [44].
According to the recent ESC 2012 guidelines on car-
diovascular prevention, the detection of an asymptom-
atic carotid plaque put subjects in the very high risk
category [43].
Therefore we suggest to investigate the presence of
preclinical atherosclerosis in all patients > 45 years old
by a carotid echo color Doppler test, because, in primary
prevention, the IMT measurement can give further in-
formation for a better stratification of global cardiovas-
cular risk [42,45]. We also recommend preventing the
development of Metabolic Syndrome’s abnormalities, en-
couraging daily physical activity and Mediterranean diet
and starting early pharmacological treatment of modifi-
able risk factors [46].
Conclusions
Preclinical atherosclerosis leads to an increased risk of
cardiovascular events, especially if it is associated with
Metabolic Syndrome. Therefore, preclinical atheroscler-
osis added to traditional risk factors can improve the
cardiovascular risk prediction [37,47], especially in pres-
ence of metabolic abnormalities.
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